IRIS
BERGANTINI, LAURA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 6.425
NA - Nord America 4.334
AS - Asia 623
SA - Sud America 19
OC - Oceania 14
AF - Africa 12
Continente sconosciuto - Info sul continente non disponibili 6
Totale 11.433
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 4.303
IT - Italia 1.886
IE - Irlanda 1.528
GB - Regno Unito 1.259
SE - Svezia 610
FR - Francia 297
DE - Germania 239
CN - Cina 213
FI - Finlandia 193
SG - Singapore 138
UA - Ucraina 103
ES - Italia 91
IN - India 83
RU - Federazione Russa 80
VN - Vietnam 64
CZ - Repubblica Ceca 59
IR - Iran 28
CA - Canada 27
HK - Hong Kong 17
TR - Turchia 14
AU - Australia 13
BE - Belgio 13
PH - Filippine 13
NL - Olanda 11
PL - Polonia 9
JP - Giappone 8
BR - Brasile 7
AT - Austria 6
CH - Svizzera 6
EU - Europa 6
PK - Pakistan 6
PT - Portogallo 6
EE - Estonia 5
DK - Danimarca 4
GE - Georgia 4
MK - Macedonia 4
NG - Nigeria 4
AR - Argentina 3
CL - Cile 3
KR - Corea 3
KZ - Kazakistan 3
LT - Lituania 3
MA - Marocco 3
PE - Perù 3
RO - Romania 3
UZ - Uzbekistan 3
ZA - Sudafrica 3
AE - Emirati Arabi Uniti 2
AZ - Azerbaigian 2
BD - Bangladesh 2
CO - Colombia 2
CR - Costa Rica 2
CY - Cipro 2
EG - Egitto 2
HR - Croazia 2
HU - Ungheria 2
ID - Indonesia 2
JO - Giordania 2
KG - Kirghizistan 2
LA - Repubblica Popolare Democratica del Laos 2
LK - Sri Lanka 2
LV - Lettonia 2
QA - Qatar 2
RS - Serbia 2
TW - Taiwan 2
AM - Armenia 1
BG - Bulgaria 1
EC - Ecuador 1
IL - Israele 1
MM - Myanmar 1
MX - Messico 1
MY - Malesia 1
NZ - Nuova Zelanda 1
PA - Panama 1
SI - Slovenia 1
Totale 11.433
Salva come PNG Salva come JPEG
Città #
Dublin 1.500
Southend 1.187
Chandler 617
Fairfield 612
Ashburn 411
Siena 351
Lastra a Signa 340
Woodbridge 230
Wilmington 223
Houston 212
Seattle 203
Princeton 184
Cambridge 179
Helsinki 178
New York 138
Ann Arbor 126
Florence 113
Singapore 86
Shanghai 70
Dong Ket 64
Jacksonville 64
Milan 62
Málaga 62
Beijing 61
Fremont 61
San Mateo 59
Rome 57
Moscow 55
San Diego 50
Boardman 47
Dearborn 47
Brno 41
Washington 27
Gavirate 24
London 24
Chicago 23
Los Angeles 21
Agliana 19
Tarazona 17
Munich 16
Olomouc 15
Livorno 14
Padova 14
Brussels 13
Hyderabad 13
Lappeenranta 12
Nanjing 12
Toronto 12
Zanjan 12
Aachen 11
Naples 11
Pune 11
Chianciano Terme 10
Comun Nuovo 10
Hong Kong 10
Pasig 10
Redwood City 10
Amsterdam 9
Bangalore 9
Guangzhou 9
Norwalk 9
Pisa 9
San Francisco 9
Grosseto 8
Izmir 8
Nanchang 8
Prato 8
Verona 8
Brescia 7
Cagliari 7
Carrara 7
Leawood 7
Salerno 7
San Casciano in Val di Pesa 7
Bergamo 6
Catania 6
Delhi 6
Falkenstein 6
Hefei 6
Kilburn 6
Paris 6
Rubano 6
Turin 6
Vienna 6
Winnipeg 6
Bari 5
Bonndorf 5
Chieti 5
Cinisello Balsamo 5
Clifton 5
Dallas 5
Jinan 5
Migliarino 5
Mumbai 5
Ponte Buggianese 5
Tallinn 5
Andover 4
Barcelona 4
Bologna 4
Canberra 4
Totale 8.334
Salva come PNG Salva come JPEG
Nome #
Alveolar concentration of nitric oxide as a prognostic biomarker in idiopathic pulmonary fibrosis 192
Prognostic Biomarkers of Sarcoidosis: A Comparative Study of Serum Chitotriosidase, ACE, Lysozyme, and KL-6 190
ACE2 gene variants may underlie interindividual variability and susceptibility to COVID-19 in the Italian population 180
Peripheral biomarkers' panel for severe COVID-19 patients 180
Genetic mechanisms of critical illness in COVID-19 175
null 171
Serial KL-6 analysis in patients with idiopathic pulmonary fibrosis treated with nintedanib 170
Chitotriosidase: a biomarker of activity and severity in patients with sarcoidosis 160
Evaluation of multiple-flows exhaled nitric oxide in idiopathic and non-idiopathic interstitial lung disease 159
The effect of cigarette smoking on bronchoalveolar lavage protein profiles from patients with different interstitial lung diseases 157
Rituximab Therapy in Interstitial Lung Disease associated with Rheumatoid Arthritis 156
Antithrombin III as predictive indicator of survival in IPF patients treated with Nintedanib: a preliminary study 151
Serum concentrations of Krebs von den Lungen-6 in different COVID-19 phenotypes 149
NK and NKT-like cells in granulomatous and fibrotic lung diseases 148
null 135
Serum amyloid A in patients with idiopathic pulmonary fibrosis 133
Ceruloplasmin and oxidative stress in severe eosinophilic asthma patients treated with Mepolizumab and Benralizumab 132
Prognostic bioindicators in severe COVID-19 patients 132
Immune modulatory effects of novel monoclonal antibodies target therapies in severe eosinophilic asthma patients 131
The polymorphism L412F in TLR3 inhibits autophagy and is a marker of severe COVID-19 in males 129
Bronchoalveolar lavage and serum KL-6 concentrations in chronic hypersensitivity pneumonitis: correlations with radiological and immunological features 123
The pathogenetic mechanisms of cough in idiopathic pulmonary fibrosis 118
Serial KL-6 measurements in COVID-19 patients 117
Systematic review and metanalysis of oncomarkers in ipf patients and serial changes of oncomarkers in a prospective italian real-life case series 116
Association of toll-like receptor 7 variants with life-threatening COVID-19 disease in males: Findings from a nested case-control study 116
Regulatory T Cells in Severe Persistent Asthma in the Era of Monoclonal Antibodies Target Therapies 111
Pirfenidone in idiopathic pulmonary fibrosis: real-life experience in the referral centre of Siena 111
Serum KL-6 concentrations as a novel biomarker of severe COVID-19 111
null 111
Alveolar nitric oxide is related to periostin levels in idiopathic pulmonary fibrosis 110
Regulatory T cell monitoring in severe eosinophilic asthma patients treated with mepolizumab 110
BAL biomarkers’ panel for differential diagnosis of interstitial lung diseases 109
The Role of Urinary Calcium and Chitotriosidase in a Cohort of Chronic Sarcoidosis Patients 109
Pathogen-sugar interactions revealed by universal saturation transfer analysis 107
Serum amyloid A: A potential biomarker of lung disorders 107
Adaptive immune system in pulmonary sarcoidosis - comparison of peripheral and alveolar biomarkers 107
Mapping the human genetic architecture of COVID-19 107
Serum CD59: a novel biomarker of idiopathic pulmonary fibrosis? 106
Adiponectin and leptin levels in idiopathic pulmonary fibrosis: A new method for BAL and serum assessment 106
Pleuroparenchymal fibroelastosis in patients affected by systemic sclerosis: What should the rheumatologist do? 101
Serial investigation of Angiotensin-Converting Enzyme in sarcoidosis patients treated with Angiotensin-Converting Enzyme Inhibitor 100
Krebs von den Lungen-6 as biomarker for disease severity assessment in interstitial lung disease: a comprehensive review 100
BAL and serum multiplex lipid profiling in idiopathic pulmonary fibrosis and fibrotic hypersensitivity pneumonitis 100
Effects of rituximab therapy on B cell differentiation and depletion 99
Idiopathic Pulmonary Fibrosis Serum proteomic analysis before and after nintedanib therapy 97
A real-life experience with ImmunoCAP ISAC: the advantages of a new diagnostic method 94
A first update on mapping the human genetic architecture of COVID-19 93
Prognostic role of KL-6 in lymphangioleiomyomatosis patients 93
Rare variants in Toll-like receptor 7 results in functional impairment and downregulation of cytokine-mediated signaling in COVID-19 patients 93
Efficacy of baricitinib in treating rheumatoid arthritis: Modulatory effects on fibrotic and inflammatory biomarkers in a real-life setting 91
Serum KL-6 levels in Pulmonary Langerhans' Cell Histiocytosis 88
Interstitial lung disease associated with psoriatic arthritis: a new disease entity? 88
Cytological analysis of bronchoalveolar lavage fluid in asbestos-exposed workers: BALF features in asbestos exposed workers 88
Comparative Serum Protein Profiles in IPF Patients Before and After Nintedanib Therapy 86
Neutrophil-to-lymphocyte ratio in bronchoalveolar lavage from IPF patients: a novel prognostic biomarker? 86
Immune-Checkpoint Expression on CD4, CD8 and NK Cells in Blood, Bronchoalveolar Lavage and Lymph Nodes of Sarcoidosis 85
Proteomic characterization of idiopathic pulmonary fibrosis patients: stable versus acute exacerbation 85
Immunologic responses to antifibrotic treatment in IPF patients 85
WES profiling of COVID-19 85
A Comprehensive Evaluation of Mepolizumab Effectiveness in a Real-Life Setting 84
Serum Concentrations of KL-6 in Patients with IPF and Lung Cancer and Serial Measurements of KL-6 in IPF Patients Treated with Antifibrotic Therapy 83
Mepolizumab and Benralizumab in Severe Eosinophilic Asthma: Preliminary Results of a Proteomic Study 82
Galactin-1, 3 and 9: Potential biomarkers in idiopathic pulmonary fibrosis and other interstitial lung diseases 81
Common molecular pathways targeted by nintedanib in cancer and IPF: a bioinformatic study 80
Integrated approach to bronchoalveolar lavage cytology to distinguish interstitial lung diseases 80
Serum Proteomic Profile of Asthmatic Patients after Six Months of Benralizumab and Mepolizumab Treatment 80
SARS-CoV-2 susceptibility and COVID-19 disease severity are associated with genetic variants affecting gene expression in a variety of tissues 79
Differential redox proteomic profiles of serum from severe asthma patients after one month of Benralizumab and Mepolizumab treatment 78
Alveolar nitric oxide as a biomarker of COVID-19 lung sequelae: A pivotal study 78
Carriers of ADAMTS13 Rare Variants Are at High Risk of Life-Threatening COVID-19 77
Metabolic Dysregulation in Idiopathic Pulmonary Fibrosis 77
A multicenter approach to evaluate omalizumab effectiveness in Samter’s triad 76
Peripheral and alveolar biomarkers of fibrotic hypersensitivity pneumonitis 75
null 75
Regulatory and Effector Cell Disequilibrium in Patients with Acute Cellular Rejection and Chronic Lung Allograft Dysfunction after Lung Transplantation: Comparison of Peripheral and Alveolar Distribution 73
Personalized Approach of Severe Eosinophilic Asthma Patients Treated with Mepolizumab and Benralizumab 72
Relapse of microscopic polyangiitis after vaccination against COVID-19: a case report 72
Clinical phenotyping in sarcoidosis management 72
Gain- and Loss-of-Function CFTR Alleles Are Associated with COVID-19 Clinical Outcomes 72
An explainable model of host genetic interactions linked to COVID-19 severity 71
Extended Exhaled Nitric Oxide Analysis in Interstitial Lung Diseases: A Systematic Review 71
Long-Term Follow-Up of Patients With Idiopathic Pulmonary Fibrosis Treated With Pirfenidone or Nintedanib: A Real-Life Comparison Study 70
Utility of serological biomarker' panels for diagnostic accuracy of interstitial lung diseases 70
Bronchoalveolar-Lavage-Derived Fibroblast Cell Line (B-LSDM7) as a new protocol for investigating the mechanisms of idiopathic pulmonary fibrosis 66
Specificity of serum amyloid A as a biomarker of idiopathic pulmonary fibrosis 65
A Comprehensive Review of Sarcoidosis Treatment for Pulmonologists 65
Protective role of a TMPRSS2 variant on severe COVID-19 outcome in young males and elderly women 63
KL-6 in ANCA-Associated Vasculitis Patients with and without ILD: A Machine Learning Approach 63
The Role of Galectins in Chronic Lung Allograft Dysfunction 61
Hypercalciuria in Sarcoidosis: A Specific Biomarker With Clinical Utility 60
Serial autoantibody detection in interstitial lung diseases: should they be repeated at follow-up? 60
Serum Amyloid A in lung transplantation 60
Multi-Omics Integrative Approach of Extracellular Vesicles: A Future Challenging Milestone 60
Prognostic role of KL-6 in SSc-ILD patients with pleuroparenchymal fibroelastosis 59
CD103 Expression on Regulatory and Follicular T Cells in Lymph Nodes, Bronchoalveolar Lavage Fluid and Peripheral Blood of Sarcoidosis Patients 58
Cytokine profiles in the detection of severe lung involvement in hospitalized patients with COVID-19: The IL-8/IL-32 axis 57
Prognostic role of NK cell percentages in bronchoalveolar lavage from patients with different fibrotic interstitial lung diseases 56
Follicular T Helper and Breg Cell Balance in Severe Allergic Asthma Before and After Omalizumab Therapy 56
BAL Proteomic Signature of Lung Adenocarcinoma in IPF Patients and Its Transposition in Serum Samples for Less Invasive Diagnostic Procedures 52
Oxygen Therapy during Exercise in Patients with Interstitial Lung Diseases 50
Totale 9.918
Salva come PNG Salva come JPEG
Categoria #
all - tutte 51.780
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 51.780
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020893 47 41 20 94 79 83 85 103 101 98 51 91
2020/20212.166 64 100 101 271 185 246 160 256 217 147 217 202
2021/20222.288 175 263 201 156 112 100 94 104 101 294 258 430
2022/20232.710 173 291 327 263 154 475 283 240 198 121 110 75
2023/20243.189 122 99 320 170 161 679 901 153 43 107 125 309
2024/2025565 565 0 0 0 0 0 0 0 0 0 0 0
Totale 11.979